ROI-NJ Interviews Health Care Partner Khaled Klele re Paused Rule Proposals
Riker Danzig Health Care and Litigation Partner, Khaled J. Klele, was interviewed by ROI-NJ for an extensive Q&A regarding health care rules proposed during President Trump’s administration that have since been frozen by President Biden’s administration. Specifically, Khaled addresses drug maker rebates, insulin and EpiPen discounts, and the “most-favored nation rule” with regard to drug pricing. In the article, “Riker Danzig’s Klele on Why Trump-era Rule Proposals Remain on Pause,” Khaled discusses what these rules mean for New Jersey health care-related businesses.
See ROI-NJ for the complete article.